Browsing: Rides

Eli Lilly & Co. (LLY)’s reign atop the red-hot GLP-1 weight-loss drug market is getting fresh validation from surging U.S. consumer adoption, as new polling shows usage nearly tripling in two years. With the drugmaker’s market value now topping $1 trillion and its stock up more than 400% over half a decade, investors are weighing…